PBMs are making it nearly impossible to navigate the waters of healthcare, writes Kreckle.
Results from a new Massachusetts Health Policy Commission report.
Government and PBMs can pursue penalties for noncompliance.
Reimbursement reform tops list of priorities, from DIR fees to rebates.
The Trump Administration has taken a large interest in PBM drug rebates, which they say create higher drug prices. But do they?
Advocates are calling for government regulations on PBMs and pharmacy.
Beginning January 2020, all new employer clients must incorporate Point-of-Sale discounts.
The dispute between the two companies highlights ongoing frustrations with the PBM model.
The September Small Doses brings you the latest news that affects pharmacists.
What the experts have to say about recent shifts in pharmacy law and practice.